← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Friends Research Institute, Inc.
Baltimore, MD
$127,055,706
Total funding
72
Grants
Funding over time
peak $9.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$123,977,764 · 68
CDC$1,965,021 · 2
AHRQ$1,112,921 · 1
SAMHSA$0 · 1
By mechanism
R01$91,585,765 · 41
UG1$11,571,703 · 1
U01$8,109,262 · 3
P50$2,278,429 · 2
R21$2,269,388 · 8
U65$1,605,967 · 1
Investigators at Friends Research Institute, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology$2,254,579
R01 · FY2022 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,231,473
UG1 · FY2020 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,216,013
UG1 · FY2021 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$2,169,367
UG1 · FY2022 · DA
Identifying Suspected Drug Overdose Deaths in Near Real-Time Using Data Collected by Death Investigators$2,099,989
R01 · FY2022 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,967,149
UG1 · FY2023 · DA
A comparative effectiveness trial of extended release naltrexone versus extended-release buprenorphine with individuals leaving jail$1,699,618
UG1 · FY2019 · DA
A patient preference trial of sublingual versus extended-release buprenorphine telemedicine and pharmacy linkage for individuals re-entering the community from jail$1,393,922
UM1 · FY2025 · DA
Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial$1,339,547
U01 · FY2021 · DA
MEDICATION DEVELOPMENT UNIT FOR STIMULANT DEPENDENCE$1,210,937
P50 · FY2003 · DA
MEDICATION DEVELOPMENT UNIT FOR STIMULANT DEPENDENCE$1,205,746
P50 · FY2002 · DA
MEDICATION DEVELOPMENT UNIT FOR STIMULANT DEPENDENCE$1,183,172
P50 · FY2001 · DA
MEDICATION DEVELOPMENT UNIT FOR STIMULANT DEPENDENCE$1,156,279
P50 · FY2000 · DA
Implementing a patient navigation intervention across a health system to improve outcomes for patients with opioid use disorder$1,130,715
R33 · FY2025 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,129,361
R01 · FY2025 · DA
A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting$1,086,043
R01 · FY2024 · DA
Implementing a patient navigation intervention across a health system to address treatment entry inequities$946,763
R61 · FY2023 · DA
Addiction Medicine Practice Based Research Network (AMNet): Addressing the Opioid Crisis$945,860
U01 · FY2019 · DA
Comparative- and cost-effectiveness research determining the optimal intervention for advancing individuals living with HIV to full viral suppression$917,615
R01 · FY2025 · DA
Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder$912,089
R01 · FY2024 · DA